Doyle Wealth Management’s Edwards Lifesciences EW Stock Holding History

Doyle Wealth Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-750	Closed	-$38K	–	351
2018 Q4	$38K	Buy	+750	New	+$37.9K	0.01%	410

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Doyle Wealth Management's EW Position: Q1 2019 in Review

Doyle Wealth Management sold out of Edwards Lifesciences (EW) in Q1 2019, closing a stake of 750 shares — an estimated $38K sold.

Doyle Wealth Management first reported a position in EW in Q4 2018 and held it in 1 quarter. The position peaked at $38K in Q4 2018. 922 funds tracked by Wall St. Rank hold EW as of Q1 2019.

Doyle Wealth Management reported no remaining Edwards Lifesciences position as of Q1 2019 after selling out during the quarter.
Doyle Wealth Management sold 750 Edwards Lifesciences shares in Q1 2019, an estimated $38K.
Doyle Wealth Management first reported a position in Edwards Lifesciences in Q4 2018 and held it in 1 quarter.
Doyle Wealth Management's Edwards Lifesciences position peaked at $38K in Q4 2018.
922 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2019.

Based on Doyle Wealth Management's 13F filing for Q1 2019, filed 13 May 2019.